Nvidia Corp vs Stryker Corporation — how do they compare? Nvidia Corp trades at $206.37 (market cap $4.92T), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Nvidia Corp is far larger — about 40.2× Stryker Corporation's market cap, and Stryker Corporation pays the higher dividend (1%). Which is the better fit depends on your goals.
| NVDA | SYK | |
|---|---|---|
Market Cap | $4.92T | $122.35B |
Sector | Technology | Technology |
52-Week High | $235.75 | $403.53 |
52-Week Low | $165.17 | $282.58 |
Enterprise Value | $4.86T | $134.10B |
Dividend Yield | 0.49% | 1% |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamentals. Recent earnings beats and robust profitability margins highlight operational strength. The stock is supported by a consensus analyst price target of $325.86, though it faces technical resistance near $210.
Outlook remains positive driven by AI chip demand, but risks include competition and market volatility. Revenue growth acceleration and high institutional ownership suggest long-term potential, yet valuation multiples require sustained execution to justify further upside.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →